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WHO medical eligibility criteria update1 The first edition was published in 2012, the second edition in 2014.
2 For further information on GRADE, see: www.gradeworkinggroup.org/
index.htm.For more than 20 years, the World Health Organization's
Department of Reproductive Health, in collaboration with its
network of international partners, has issued evidence-based
guidance on the safety of various contraceptive methods for
women and men with particular medical conditions or
personal characteristics. This guidance, the medical eligibil-
ity criteria for contraceptive use or MEC, offers national
family planning programs a comprehensive set of recom-
mendations on whether a woman or man is eligible or not to
use a particular contraceptive method. The MEC was
conceived as a global normative reference for policy makers
and program managers to use when developing their national
policies and programs, with the overarching goal of
removing unnecessary medical barriers to contraception.
To this very day, the MEC continues to serve this specific
purpose, as well as contribute toward ensuring sexual and
reproductive rights.
Recognition of the importance and societal benefits of
universal access to high-quality sexual and reproductive
health services and investing in family planning, in
particular, by the international community continues to
receive prominent attention [1]. Reducing unmet need for
family planning was included as one of the key indicators for
achieving Millennium Development Goal 5 (MDG 5:
improving maternal health). Additionally, reducing unmet
need was linked with achieving MDG 4 (reducing child
mortality) and MDG 6 (combating HIV/AIDS, malaria and
other diseases) [2]. A recent analysis shows that achievement
of the five Sustainable Development Goal themes of people,
planet, prosperity, peace and partnership depends on
investments in family planning [3]. Adding to these global
frameworks, in 2012 governments, donors, nongovernmen-
tal organizations and civil society convened to establish a
global movement to reduce unmet need for family planning
and reach 120 million new users of contraception by the year
2020. Guidance within the MEC has played, and will
continue to do so, an important role in contributing toward
all of these goals.
During the years since the publication of the MEC first
edition in 1996, the World Health Organization (WHO)
produced revisions of the MEC in 2000, 2003 and 2009.http://dx.doi.org/10.1016/j.contraception.2016.07.001
0010-7824/© 2016 Elsevier Inc. All rights reserved.With each revision, we added new contraceptive methods
and new medical conditions to the guideline to optimize the
document's usefulness and respond to the needs of national
programs. In several instances, WHO issued interim
guidance when important new evidence became available
between the revisions. This interim guidance (addressing
bone health, postpartum venous thromboembolism risk and
HIV acquisition risk) was published separately and then
incorporated into the subsequent fully revised MEC
guideline.
Most recently, WHO convened a series of Guideline
Development Group (GDG) meetings on 14–15 May 2013,
9–12 March 2014 and 24–25 September 2014, to develop
the fifth edition of the MEC. The GDG consisted of 68
individuals representing a wide range of specialised areas
(i.e., obstetrics & gynecology, pharmacology, endocrinolo-
gy, epidemiology, demography, cardiology, program man-
agement, biostatistics and family medicine). To prepare the
fifth edition, WHO adjusted several key aspects of the
revision process to be in closer alignment with requirements
set forth in the WHO Handbook for Guideline Development,
authored by the GRC Secretariat.1 Specifically, these
alterations included
• creation of groups with varying roles to undertake the
revision;
• convening an additional consultation to define the
scope of the revision, giving priority to controversial
topics and those for which new evidence had emerged,
including topics addressed in interim guidance,
clarifying recommendations with a Category 2/3
classification, and drafting questions relating to
population, intervention, comparator and outcome
(PICO questions) to guide the preparation of system-
atic reviews; and
• applying the Grading Recommendations, Assessment,
Development and Evaluation (GRADE) approach to
evidence review and recommendation formulation.2
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review of the following: (a) six topics identified as important
to the field and/or those topics with new evidence that may
warrant a change in the existing recommendation; (b) two topics
for which interim guidancewas issued following the publication
of the fourth edition; (c) contraceptive eligibility recommenda-
tions for the inclusion of four new contraceptive methods in the
fifth edition; and (d) two topics to provide greater clarity for the
recommendations in the fourth edition relating to these topics, at
the request of the Guidelines Review Committee. In total, 14
topics encompassing over 575 recommendationswere reviewed
for the fifth edition of the MEC.
As a result of the GDG's efforts, four new contraceptive
methods appear in the fifth edition: DMPA-SC, a subcuta-
neously administered version of DMPA; ulipristal acetate for
emergency contraception; Sino-implant (II), a levonorgestrel
subdermal implant; and the progesterone-releasing vaginal
ring for use among breastfeeding women. In response to
advances in HIV care, recommendations are now available
for four main classes of antiretroviral medications (ARVs),
and within each class, recommendations address individual
ARV medications. For emergency contraception, two new
conditions were added: obesity and CYP3A4 inducers.
Reflecting current clinical practices, the terminology for
several conditions has been updated, namely: HIV/AIDS is
now termed as either (a) asymptomatic or mild HIV clinical
disease (WHO stage 1 or 2) or (b) severe or advanced HIV
clinical disease (WHO stage 3 or 4); known hyperlipidemia
is now labeled known dyslipidemias without other cardio-
vascular risk factors; and the condition superficial venous
thrombosis is now termed superficial venous disorders, with
an updated subcondition, superficial venous thrombosis
(replacing superficial thrombophlebitis).
WHO and collaborating colleagues are pleased to publish
seven systematic reviews in this issue of Contraception. These
systematic reviews address topics that have been a great source
of concern or confusion. Publication of these papers should
provide greater clarity on a woman's eligibility to use
progestogen-only contraceptives during breastfeeding; use
combined hormonal contraceptives during breastfeeding; use
combined hormonal contraceptives if she has superficial venous
disease or has known dyslipidemias; use the progesterone-r-
eleasing vaginal ring during breastfeeding; use the Sino-Implant
(II); or use the subcutaneously administered DMPA injectable.
Given its commitment to ensure that these recommendations
remain up-to-date with the published evidence that supports
these recommendations, WHO will continue to monitor the
emerging relevant evidence as it is identified through the
Continuous Identification of Research Evidence (CIRE) system
and take action as needed. [4] WHO welcomes comments and
suggestions to improve the guideline (hrx-info@who.int).The full MEC guidance can be found at http://www.who.int/
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